Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | AQP1 | P29972 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963002 | 0.89 | NPC1 (0.37) | NPC1L3MBTL1RAB9AHTTMAP3K14 | |
| SCHEMBL4962999 | 0.89 | NPC1 (0.37) | NPC1L3MBTL1RAB9AHTTMAP3K14 | |
| SCHEMBL4960249 | 0.84 | NPC1 (0.39) | NPC1L3MBTL1CA2TAAR1AQP1 | |
| SCHEMBL4960250 | 0.84 | NPC1 (0.39) | NPC1L3MBTL1CA2TAAR1AQP1 | |
| SCHEMBL4962953 | 0.82 | NPC1 (0.33) | NPC1L3MBTL1AQP1HTTLMNA | |
| SCHEMBL4962960 | 0.82 | NPC1 (0.33) | NPC1L3MBTL1AQP1HTTLMNA | |
| SCHEMBL4964065 | 0.81 | CA2 (0.40) | NPC1L3MBTL1CA2HTR7AQP1 | |
| SCHEMBL4962751 | 0.81 | CA2 (0.33) | NPC1L3MBTL1CA2AQP1CA1 | |
| SCHEMBL4964058 | 0.81 | CA2 (0.40) | NPC1L3MBTL1CA2HTR7AQP1 | |
| SCHEMBL4960027 | 0.80 | HTR2A (0.33) | NPC1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | NPC1 3515/4885L3MBTL1 3726/4885CA2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.